Ludwig's genomic-based
mRNA Inflammatory Index - a Ground-Breaking Technology
Sparks, NV
-- September 28, 2022 -- InvestorsHub NewsWire
-- (OTC
PINK:LUDG) Ludwig
Enterprises, a
leading-edge innovator of genetic inflammatory biomarkers to
diagnose and manage chronic diseases, is pleased to announce more
detail on this crucial technology, cooperative contracts, and
current applications.
This
technology's potential medical and commercial value is revealed in
a Research and Markets via Business Wire titled: "Global
Biochips Market Report 2022: Increasing Adoption of Personalized
Medicine Drives Growth." "The
rising prevalence of chronic diseases, such as cancer and diabetes,
has increased demand for early diagnosis. In addition, the
increasing adoption of personalized medicine and point-of-care
(POC) testing is estimated to propel market growth." "Global
biochip market expected to reach USD 34.35 billion in
2030."*
The Ludwig mRNA
Inflammatory Index is ground-breaking technology that has the
potential to transform how inflammatory diseases are diagnosed and
managed. Ludwig Enterprises (Ludwig) recently filed a vital
industry patent. The patent covers messenger ribonucleic acid
(mRNA) application in diagnosing, managing, and evaluating patient
treatment response in chronic inflammatory-based diseases, such as
heart disease, diabetes, preeclampsia, and cancer. Ludwig
Enterprises contracts with the
Genetic Institute of America (GIA) to use
their
Thermo Fisher Scientific, Inc. (Thermo
Fisher) automated robotic systems for patient specimen handling and
mRNA measurements.
The mRNA primers used by
Ludwig are produced by Thermo Fisher, a company mentioned in the
biochip report. Ludwig's patient specimen bank has greater than 200
buccal (cheek) cell samples awaiting evaluation. The rising
prevalence of chronic diseases, such as heart disease, cancer, and
diabetes, has increased the demand for early diagnosis.
How
the Ludwig mRNA Inflammatory Index Works
The Ludwig mRNA Inflammatory Index is a genetic test that discovers
the degree of inflammation in your body by calculating levels of
mRNA-expressed biomarkers, such as cytokines. Cytokines are
substances the immune system produces, influencing other cells and
essentially upregulating the inflammatory response.
Why
the Ludwig mRNA Inflammatory Index is important
The Ludwig
Index has the potential to create a genetic signature in patients
with chronic disease. This genetic signature provides a potential
framework for chronic inflammatory disorders, such as heart
disease, diabetes, preeclampsia, and cancer, to optimize early
diagnosis and clinical management with appropriate
therapy.
The Application of Artificial Intelligence (AI)
Ludwig's AI
program will use deep machine learning to discover hidden gene
patterns related to the inflammatory causation of specific
diseases. The objective is to develop a computational model that
provides a genetic picture of actionable events that can be used to
improve healthcare.
Current Study
The Ludwig mRNA Inflammatory Index™ will be used in the recent
announcement: "Ludwig
Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG
Immunotherapy Study.
"The Ludwig mRNA
Inflammatory Index is a ground-breaking technology that has the
potential to revolutionize how we diagnose and treat inflammatory
diseases. With its ability to measure inflammation in the body, it
has the potential to provide earlier diagnosis and more effective
treatment for many common chronic diseases. We are just beginning
to scratch the surface of what this technology can do, and I am
excited to see what the future holds for this incredible
invention." - said Ludwig CEO Anne Blackstone.
About Ludwig
Enterprises, Inc.: Advancements in medical technology have awarded
us with cutting-edge genetic tools, unheard-of even a generation
ago. These genetic tools have the potential to not only detect
diseases early but also to customize treatments that may improve
patient outcomes and, in some cases, even extend life. Ludwig is at
the forefront of this new era of medicine with their proprietary
mRNA genetic methodology that has the potential to detect genetic
biomarkers for inflammatory-driven diseases, including but not
limited to heart disease, preeclampsia, and cancer. This early
detection may allow doctors to take steps to diagnose and manage
disease before it progresses and causes serious health problems.
Ludwig's innovative testing approach is not only practical but also
has the potential to save the healthcare industry billions of
dollars in costs. With a virtually untapped market and a
billion-dollar healthcare industry, Ludwig is poised to
significantly impact how we think about disease and live longer,
healthier lives. More Info:
http://www.ludwigent.com
SAFE
HARBOR
Forward-looking
statements in this release are made under the "safe harbor"
provision of the Private Securities Litigation Reform Act of 1995.
Ludwig Enterprises Inc.'s forward-looking statements are not a
guarantee of future performance. This news release includes
forward-looking statements concerning the future level of business
for the parties. These statements are necessarily subject to risk
and uncertainty. Actual results could differ materially from those
projected in these forward-looking statements due to certain risk
factors that could cause results to differ materially from
estimated results. Management cautions that all statements as to
future results of operations are necessarily subject to risks,
uncertainties, and events that may be beyond the control of Ludwig
Enterprises, Inc., and no assurance can be given that such results
will be achieved. Potential risks and uncertainties include, but
are not limited to, the ability to procure, appropriately priced,
retain, and complete projects and changes in products and
competition.
CONTACT:
Ludwig
Enterprises,
Anne
Blackstone,
786-235-9026